The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany

Peter Bramlage, Sascha R Tittel, Christian Wagner, Kerstin König, Dirk Raddatz, Rosmarie Weber-Lauffer, Diether Erath, Jost Hilgenberg, Carsten Spies, Thomas Danne, Maximilian Gabler, Johannes Foersch, Ludwin Ley, Jochen Seufert

ABSTRACT

Introduction Empagliflozin reduced morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) in clinical trials. A registry study was undertaken to describe evolution of patient characteristics and assess the real-world effectiveness/safety of empagliflozin.

Research design and methods Data from the Diabetes Patienten Verlaufsdocumentation (DPV)/Diabetes Versorgungsevaluation (DIVE) registries on 9571 adults with T2DM (registered in 2014–2019) receiving empagliflozin were used. Patients were grouped according to the following: early users (group 1; n=505) received empagliflozin before the EMPA-REG OUTCOME study publication (mid-September 2015); intermediate users (group 2; n=2961) started empagliflozin after the EMPA-REG OUTCOME publication but before the European Medicines Agency label change (from mid-September 2015 to mid-January 2017); and late users (group 3; n=6105) started empagliflozin after mid-January 2017. Data on clinical and treatment characteristics were collected.

Results Over time, the proportion of recipients aged <65 years decreased (71.1% vs 54.4% among early and late adopters), male patients increased (from 50.9% to 66.5%), body mass index (mean±SD) decreased (from 35.5±6.7 to 32.7±6.6 kg/m²), proportion with cardiovascular morbidities increased (from 20.4% to 26.4%), and mean estimated glomerular filtration rate decreased (from 83.2±19.5 to 78.5±21.1 mL/min/1.73 m²) (all p<0.001). Patients increasingly received empagliflozin in combination with metformin (60.8% vs 68.6% of early and late adopters; p<0.001), glucagon-like peptide-1 (GLP-1) agonists (11.0% vs 14.1%; p<0.001) or insulin (34.3% vs 49.9%; p<0.001). Empagliflozin was generally added to existing antidiabetic regimens. Six months after empagliflozin initiation, the mean glycated hemoglobin (HbA1c) decreased by 0.4%, the mean fasting plasma glucose decreased (155.8±49.7 vs 168.0±55.1 mg/dL) (all p<0.001). No significant changes in rates of severe hypoglycemia and no cases of diabetic ketoacidosis were seen.

Conclusions Over time, empagliflozin is being prescribed to a broader patient range in routine practice, is usually added to existing antidiabetic regimens, and is increasingly used in combination with metformin, GLP-1 agonists and/or insulin. Empagliflozin had a beneficial effect on glycemic control, with no increase in hypoglycemia.

BACKGROUND

Empagliflozin is a recently introduced antidiabetic drug of the sodium-glucose cotransporter-2 (SGLT-2) inhibitor drug class which has been shown to reduce morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) was the first specific outcome study to show cardiovascular and renal benefits for a
non-insulin glucose-lowering drug versus placebo, when added to standard of care. It has high bioavailability, high selectivity for SGLT-2 over SGLT-1 and a relatively long half-life of 15.2 hours compared with other SGLT-2 inhibitors.

While the clinical trial-based development of empagliflozin for the treatment of T2DM may be regarded as complete, further data are necessary to understand the real-world implications of its use. This not only includes the description of its use in patients who may not have been eligible for one of the pivotal studies, but also the real-world effectiveness and safety of the drug. For this purpose, we evaluated registry data on recipients of empagliflozin, divided into three groups based on when they started treatment with the drug. Group 1 included patients in whom treatment with empagliflozin was initiated before the EMPA-REG OUTCOME study results were reported (ie, before mid-September 2015). Group 2 included patients who were initiated on the drug between mid-September 2015 and the time when the European Medicines Agency (EMA) changed the label wording from ‘improvement of glycaemic control’ to the more general ‘treatment of adults with insufficiently controlled T2DM’, with reference to ‘effects on glycaemic control and cardiovascular events’ (mid-January 2017). Group 3 included all patients started on empagliflozin thereafter, that is, from mid-January 2017 onwards.

We aimed to describe the evolution of patient characteristics over time, to assess the real-world effectiveness of empagliflozin, and to describe the rates of adverse effects such as hypoglycemia and ketoacidosis.

**Methods**

**Study design and data sources**

This analysis used combined data from the Diabetes Patienten Verlaufsdocumentation (DPV) and Diabetes Versorgungsevaluation (DIVE) registries. Their design has been described previously. Briefly, the DPV initiative collects data on patients with diabetes mellitus from centers predominantly in Germany. Data are collected every 6 months using DPV software and then sent anonymized to the University of Ulm for aggregation into the cumulative database.

The DIVE registry was established in 2011. Consecutive patients with diabetes mellitus, regardless of disease stage, were enrolled from centers across the country, and continue to be followed up. Data are entered into an online database using DPV software. All patients included in the DIVE registry provided written informed consent.

A total of 216 centers from Germany, Austria, Switzerland and Luxemburg were included in the present analysis. Patients were sampled in September 2019 and included in the current analysis if they had T2DM, were at least 18 years old, were initially registered between 2014 and 2019, and received empagliflozin either as a single-drug pill or in combination with other drugs.

**Documentation**

For the current analysis, data regarding age, sex, body mass index (BMI), blood pressure, renal parameters, antidiabetic and antihypertensive drug treatment, and current comorbidities were collected. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Chronic kidney disease (CKD) was defined as eGFR <60 mL/min/1.73 m² or eGFR ≥60 mL/min/1.73 m² plus albuminuria (urinary albumin to creatinine ratio ≥30 mg/g). Severe hypoglycemia was defined as the need of assistance from another person, a self-monitoring of blood glucose value of ≤56 mg/dL (≤3.0 mmol/L) or hospitalization.

**Analysis**

The analysis describes the real-life treatment of adult patients with T2DM receiving empagliflozin, comparing the characteristics of patients starting empagliflozin in three time periods. The first analysis group included patients who were receiving empagliflozin before the EMPA-REG OUTCOME study was published (ie, before mid-September 2015; ‘Group 1’, early adopters). The second analysis group included patients who started receiving empagliflozin after the EMPA-REG OUTCOME study results were published but before EMA label change (ie, between mid-September 2015 and mid-January 2017; ‘Group 2’, intermediate adopters). The third analysis group included those patients who started receiving empagliflozin between mid-January 2017 and the last available data cut in September 2019 (‘Group 3’, late adopters).

**Statistics**

Data from all patients within a group were combined and analyzed as a single data set. Categorical variables are presented as percentages. Continuous variables are presented as mean with SD. Unadjusted comparisons were conducted using χ² or Kruskal-Wallis test. The Bonferroni stepdown method was used to correct p values for multiple testing. A p value <0.05 was considered statistically significant. Statistical analysis was performed using SAS V.9.4.

**Results**

A total of 9571 patients with T2DM who received empagliflozin treatment were included in the analysis (figure 1). A marked increase in the number of patients treated with empagliflozin was seen over time: 505 patients were classified as early adopters (ie, started the drug before mid-September 2015), 2961 as intermediate adopters (ie, started between mid-September 2015 and mid-January 2017), and 6105 as late adopters (ie, started after mid-January 2017).

**Patient characteristics**

Baseline patient characteristics are summarized in table 1. In all three time periods, empagliflozin was...
Cardiovascular and Metabolic Risk

most commonly initiated in younger patients, but over time it was increasingly prescribed to older patients, with the proportion of recipients aged <65 years decreasing from 71.1% among early adopters to 54.4% among late adopters (p<0.001). The proportion of male patients increased over time, from 50.9% to 66.5% (p<0.001).

BMI (mean±SD) decreased from 35.5±6.7 kg/m² among early adopters to 32.7±6.6 kg/m² among late adopters (p<0.001). The proportion of patients with cardiovascular morbidities increased over time (from 20.4% to 26.4%; p<0.001), and the mean eGFR decreased from 83.2±19.5 mL/min/1.73 m² in early adopters to 78.5±21.1 mL/min/1.73 m² in late adopters (p<0.001).

Drug treatment
Concomitant drug treatment is summarized in table 2. Over time, empagliflozin was increasingly used in patients being treated with different cardiovascular drugs, including antihypertensive drugs, lipid-lowering agents and antplatelets/anticoagulants (all p<0.001).

The proportion of patients receiving concomitant sulfonylurea treatment decreased over time (p<0.001), as did the proportion receiving acarbose (although this did not achieve statistical significance), whereas an increasing number of patients received empagliflozin in combination with metformin (60.8% of early adopters vs 68.6% of late adopters; p<0.001). There was a marked increase in the proportion of patients receiving empagliflozin in conjunction with insulin (from 34.3% of early adopters to 49.9% of late adopters; p<0.001).

Switch analysis
The results of a switch analysis of glucose-lowering treatments are shown in table 3. The data suggest that, in general, empagliflozin did not replace other drugs, but was added to the antidiabetic regimen. This was seen for non-insulin-based antidiabetic therapy, where an increase in two-drug and three-drug combinations was observed (p<0.001), as well as for insulin-based regimens, where there was an increase from 23.1% of patients prior to empagliflozin initiation to 42.4% after initiation of empagliflozin (p<0.001).

Effectiveness and safety
A comparison of effectiveness and safety parameters prior to empagliflozin initiation and at 6 months after initiation of empagliflozin is provided in table 4. The mean glycated hemoglobin (HbA1c) significantly decreased by 0.4% points (from 7.8% to 7.4%; p<0.001) at the 6-month timepoint compared with the value prior to empagliflozin initiation (p<0.001), and the proportion of patients with HbA1c <6.5% was significantly greater at the 6-month timepoint (19.2% vs 12.8%; p<0.001). The mean fasting plasma glucose also decreased significantly, from 168.0±55.1 to 155.8±49.7 mg/dL (p<0.001). There was no increase in the rate of severe hypoglycemia after starting empagliflozin treatment. No case of diabetic ketoacidosis occurred after start of empagliflozin during the study follow-up. No significant effect on the rate of CKD was seen.

DISCUSSION
The principal findings of this analysis investigating the use of empagliflozin in routine clinical practice were as follows. In recent years, older patients, more male patients, and more patients with substantial cardiovascular comorbidity are being treated with empagliflozin. Empagliflozin is usually being added to an antidiabetic regimen, rather than replacing other antidiabetic drugs.
Cardiovascular and Metabolic Risk

It is increasingly being used in dual and triple combinations with metformin or glucagon-like peptide-1 (GLP-1) agonists or together with insulin. Empagliflozin provides a beneficial effect on glycemic control, with no increase in the rates of severe hypoglycemia.

Patient characteristics

The comparably low number of empagliflozin patients is surprising, especially when considering that in the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) Health Technology Assessment (HTA) procedure in September 2016 the Federal Joint Committee (G-BA) granted empagliflozin a considerable additional benefit for the treatment of patients with T2DM with established cardiovascular disease (eCVD). Generally, there are no specific prescribing limitations for specialists in Germany. Indeed, the National Association of Statutory Health Insurance Physicians in collaboration with the Drug Commission of the German Medical Association recommended empagliflozin use prior to sitagliptin and saxagliptin in patients with T2DM/eCVD. However, there are different drug agreements on a regional level with lead substances, minimum and maximum quotas that can impact specialists’ prescription behavior.

The results of the study, however, suggest that the population of patients being prescribed empagliflozin is broadening over time and that it is being prescribed

Table 1  Patient characteristics according to period of empagliflozin treatment initiation

|                               | Total               | Group 1 (early adopters) | Group 2 (intermediate) | Group 3 (late adopters) | P value |
|------------------------------|---------------------|--------------------------|------------------------|-------------------------|---------|
| Age, years, mean (SD)        | 62.4 (11.5)         | 59.2 (11.3)              | 61.2 (11.5)            | 63.2 (11.4)             | <0.001  |
| <65, %                       | 57.3                | 71.1                     | 60.8                   | 54.4                    | <0.001  |
| 65–<75, %                    | 27.9                | 20.0                     | 27.4                   | 28.9                    | 0.001   |
| 75–80, %                     | 10.1                | 6.5                      | 8.3                    | 11.3                    | <0.001  |
| >80, %                       | 4.7                 | 2.4                      | 3.6                    | 5.4                     | <0.001  |
| Gender, male, %              | 64.2                | 50.9                     | 61.8                   | 66.5                    | <0.001  |
| BMI, kg/m², mean (SD)        | 33.3 (6.8)          | 35.5 (6.7)               | 33.9 (7.1)             | 32.7 (6.6)              | <0.001  |
| Height, cm, mean (SD)        | 172.1 (9.7)         | 170.5 (9.5)              | 171.8 (9.9)            | 172.3 (9.6)             | <0.001  |
| Weight, kg, mean (SD)        | 98.6 (22.2)         | 103.2 (21.4)             | 100.3 (23.1)           | 97.3 (21.7)             | <0.001  |
| Diabetes management program participants, % | 38.2                | 53.5                     | 48.6                   | 31.8                    | <0.001  |
| Duration of diabetes, years, mean (SD) | 11.0 (8.4)          | 10.7 (7.8)               | 10.8 (8.2)             | 11.2 (8.5)              | 0.475   |
| HbA1c, %, mean (SD)          | 8.3 (1.8)           | 8.2 (1.7)                | 8.3 (1.7)              | 8.4 (1.9)               | 0.475   |
| mmol/mol, mean (SD)          | 67.4 (19.8)         | 65.7 (18.4)              | 66.6 (18.7)            | 67.8 (20.4)             | 0.475   |
| FPG, mg/dL, mean (SD)        | 181.7 (78.3)        | 186.0 (85.6)             | 182.3 (76.5)           | 181.1 (78.5)            | 1.000   |
| Cardiovascular comorbidities, % | 24.6                | 20.4                     | 21.6                   | 26.4                    | <0.001  |
| Myocardial infarction, %     | 6.7                 | 3.0                      | 4.5                    | 8.1                     | <0.001  |
| Stroke, %                    | 3.6                 | 1.8                      | 3.0                    | 4.1                     | 0.031   |
| Coronary artery disease, %   | 14.3                | 11.3                     | 12.0                   | 15.7                    | <0.001  |
| Peripheral arterial disease, % | 11.3               | 10.7                     | 10.8                   | 11.6                    | 1.000   |
| Congestive heart failure, %  | 1.1                 | 0.0                      | 0.7                    | 1.4                     | 0.123   |
| Diabetes late complications, % | 59.1                | 59.6                     | 57.6                   | 59.8                    | 0.835   |
| Neuropathy, %                | 40.4                | 43.6                     | 39.8                   | 40.4                    | 1.000   |
| Nephropathy, %               | 38.7                | 36.1                     | 39.1                   | 38.8                    | 1.000   |
| Chronic kidney disease, %    | 38.7                | 36.1                     | 39.1                   | 38.8                    | 1.000   |
| Microalbuminuria, %          | 36.0                | 37.5                     | 40.1                   | 34.1                    | 0.002   |
| Macroalbuminuria, %          | 5.5                 | 1.1                      | 4.5                    | 6.4                     | 0.001   |
| eGFR, mL/min/1.73 m², mean (SD) | 79.6 (21.0)         | 83.2 (19.5)              | 81.4 (20.6)            | 78.5 (21.1)             | <0.001  |
| Diabetic foot syndrome, %    | 7.0                 | 10.1                     | 7.5                    | 6.6                     | 0.072   |
| Retinopathy, %               | 8.4                 | 5.4                      | 6.5                    | 9.7                     | 0.060   |
| Proliferative, %             | 1.7                 | 0.5                      | 1.5                    | 1.9                     | 1.000   |
| Non-proliferative, %         | 6.6                 | 4.8                      | 4.9                    | 7.7                     | 0.118   |

BMI, body mass index; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin.
### Table 2  Concomitant drug treatment according to period of empagliflozin initiation

|                          | Total | Group 1 (early adopters) | Group 2 (intermediate) | Group 3 (late adopters) | P value |
|--------------------------|-------|--------------------------|------------------------|-------------------------|---------|
| Antihypertensive drugs, %| 55.8  | 45.4                     | 49.5                   | 59.8                    | <0.001  |
| ACEI, %                  | 27.9  | 21.2                     | 24.7                   | 30.0                    | <0.001  |
| ARB, %                   | 19.2  | 16.8                     | 17.7                   | 20.1                    | 0.083   |
| Beta-blockers, %         | 31.4  | 19.6                     | 25.8                   | 35.1                    | <0.001  |
| Diuretics, %             | 25.5  | 17.8                     | 21.9                   | 27.9                    | <0.001  |
| Calcium antagonists, %   | 17.9  | 12.5                     | 15.4                   | 19.5                    | <0.001  |
| Lipid-lowering agents, % | 42.1  | 28.3                     | 36.4                   | 46.0                    | <0.001  |
| Statins, %               | 39.9  | 26.1                     | 34.2                   | 43.8                    | <0.001  |
| Ezetimibe, %             | 2.9   | 1.4                      | 2.1                    | 3.4                     | 0.004   |
| Other non-statin LLT, %  | 2.9   | 3.4                      | 2.8                    | 2.9                     | 0.803   |
| Antiplatelet, anticoagulant drugs, % | 22.1 | 11.7 | 17.4 | 25.3 | <0.001 |
| Platelet aggregation inhibitors, % | 19.0 | 11.7 | 15.1 | 21.5 | <0.001 |
| Oral anticoagulants, %  | 5.1   | 0.0                      | 4.2                    | 5.8                     | <0.001  |
| Glucose-lowering therapies, % | 87.7 | 80.2 | 83.1 | 90.6 | <0.001 |
| Insulin, %               | 45.1  | 34.3                     | 37.2                   | 49.9                    | <0.001  |
| Metformin, %             | 65.4  | 60.8                     | 59.7                   | 68.6                    | <0.001  |
| Acarbose, %              | 0.6   | 1.0                      | 0.9                    | 0.4                     | 0.157   |
| Sulfonyurea, %           | 5.8   | 9.3                      | 6.8                    | 5.0                     | <0.001  |
| DPP-4 inhibitors, %      | 31.2  | 25.2                     | 31.1                   | 31.8                    | 0.071   |
| GLP-1 agonists, %        | 13.2  | 12.1                     | 12.2                   | 13.9                    | 0.317   |
| SGLT2 inhibitors other than empagliflozin, % | 2.9 | 7.9 | 2.3 | 2.7 | <0.001 |

ACEI, ACE inhibitor; ARB, angiotensin-receptor blocker; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; LLT, lipid-lowering therapy; SGLT-2, sodium-glucose transport protein-2.

### Table 3  Glucose-lowering treatment prior to versus post empagliflozin initiation: switch analysis

| Drug classes                        | Prior to empagliflozin initiation | After empagliflozin initiation | P value |
|-------------------------------------|-----------------------------------|-------------------------------|---------|
| Drug classes                        | Metformin, %                      | 51.1                          | 62.2    | <0.001  |
|                                   | Acarbose, %                       | 0.5                           | 0.5     | 0.781   |
|                                   | Sulfonyurea, %                    | 7.4                           | 6.1     | 0.055   |
|                                   | DPP-4 inhibitors, %               | 25.8                          | 28.3    | 0.035   |
|                                   | GLP-1 agonists, %                 | 11.0                          | 14.1    | <0.001  |
|                                   | SGLT2 inhibitors, %               | 6.3                           | 100     | <0.001  |
|                                   | Empagliflozin, %                  | 0                             | 100     | <0.001  |
|                                   | Any other, %                      | 6.3                           | 3.8     | <0.001  |
|                                   | Insulin, %                        | 29.3                          | 42.4    | <0.001  |
| Drug–drug combination therapy      | Single drug, %                    | 27.3                          | 26.1    | 0.602   |
|                                   | Two-drug combinations without insulin, % | 16.6 | 28.3 | <0.001  |
|                                   | Three-drug combinations without insulin, % | 2.9 | 14.5 | <0.001  |
|                                   | Combinations including insulin, % | 23.1                          | 42.4    | <0.001  |

DPP4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; SGLT-2, sodium-glucose transport protein-2.
Cardiovascular and Metabolic Risk

Table 4 Real-world effectiveness and safety

|                          | Within 1 year prior to empagliflozin initiation | 3–9 months after empagliflozin initiation | P value |
|--------------------------|------------------------------------------------|------------------------------------------|---------|
| HbA1c, %, mean (SD)*     | 7.8 (1.3)                                      | 7.4 (1.1)                                | <0.001  |
| mmol/mol, mean (SD)      | 61.9 (14.5)                                    | 57.3 (11.8)                              | <0.001  |
| HbA1c <6.5%, %           | 12.8                                           | 19.2                                     | <0.001  |
| HbA1c ≥6.5% and <7.0%, % | 15.4                                           | 19.8                                     | <0.001  |
| HbA1c ≥7.0% and <7.5%, % | 19.0                                           | 22.1                                     | 0.013   |
| HbA1c ≥7.5% and <8.0%, % | 17.1                                           | 16.3                                     | 0.635   |
| HbA1c ≥8.0%, %           | 35.8                                           | 22.7                                     | <0.001  |
| FPG, mmol/mol, mean (SD) | 168.0 (55.1)                                   | 155.8 (49.7)                             | <0.001  |
| Severe hypoglycemia, %   | 0.6                                            | 0.4                                      | 0.430   |
| Chronic kidney disease, %| 43.6                                           | 40.3                                     | 0.070   |
| Diabetic ketoacidosis, % | 0.03                                           | 0.0 (n=0)                                | 0.635   |

*The HbA1c differs from table 1 as only a subgroup of patients available for this analysis were considered.

FPG, fasting plasma glucose; HbA1c, glycated hemoglobin.

earlier in the treatment algorithm. This could be a consequence of prescribers gaining greater experience with the drug, and the availability of clinical trial results supporting its beneficial effects on major cardiovascular and renal outcomes in patients with T2DM, leading to updates of the product label, as well as respective treatment guidelines worldwide.

Although empagliflozin is most commonly prescribed to younger patients (aged <65 years), it is increasingly being used in older patients, too. The proportion of recipients having cardiovascular comorbidities, such as a history of myocardial infarction, coronary artery disease or stroke, has also increased. These two findings may be related, as comorbidity tends to increase with age. Use of empagliflozin in older patients and those with comorbidities increased after the publication of the results of the EMPA-REG OUTCOME study, which showed that empagliflozin treatment was associated with a reduced risk of adverse cardiovascular outcomes and death compared with placebo, when added to standard care in patients with T2DM who were at high cardiovascular risk.1

The mean eGFR decreased between early and late adopters of empagliflozin in the current study, suggesting that an increasing number of patients with low eGFR are being treated with empagliflozin. Prescribers may have been reassured by data from the EMPA-REG OUTCOME study showing that the beneficial renal effects (ie, slower progression of kidney disease) of empagliflozin were independent of renal function and HbA1c. Furthermore, the safety profile was consistent across the eGFR spectrum down to 30 ml/min/1.73 m².2

Empagliflozin treatment is known to lead to a reduction in bodyweight.11 The decrease in mean BMI seen between early and late adopters suggests that empagliflozin was initially used in patients with high BMI but is now also being used in patients with lower BMI.

Drug–drug combinations

The study shows that in recent years, empagliflozin is increasingly often being prescribed in conjunction with metformin. Metformin is the first-line oral glucose-lowering medication for most patients with T2DM; however, as the disease progresses, many patients need combination therapy to maintain adequate reductions in glucose levels. The combination of metformin and empagliflozin has been shown to improve glycemic control compared with either agent alone, with a low risk of hypoglycemia.12–14 It has also been shown to be superior to the combination of metformin and glimepiride in HbA1c change from baseline in a 2-year study, while reducing non-severe hypoglycemia by more than 20% (>90% relative risk reduction).15

A switch analysis of previous glucose-lowering treatment showed that empagliflozin was generally not introduced as a replacement for other drugs but was usually added to the antidiabetic regimen. Actually more than a quarter of patients received triple combination therapy, which is in line with the German Diabetes Guideline16 recommending the oral triple combination of metformin, a dipeptidyl peptidase-4 inhibitor and SGLT-2 inhibitor as a safe, effective and simple treatment regimen based on clinical trial evidence.171819 The triple combination offers sustained reductions in HbA1c, fasting blood glucose, weight and blood pressure with a low rate of hypoglycemia, but at the costs of known side effects of each of these drugs.

In patients with T2DM in whom glycemic targets cannot be achieved with oral agents, basal insulin therapy can be added.20 It has been shown that the addition of empagliflozin to basal insulin improves glycemic control with no increased risk of hypoglycemia.21 This was confirmed in a trial published by Rosenstock et al. where the addition of empagliflozin to multiple daily injections of insulin in obese patients with T2DM improved glycemic control and reduced weight without increasing the risk of hypoglycemia.
and with lower insulin requirements.\textsuperscript{22} The current study found a marked increase in the use of empagliflozin in combination with insulin in more recent time periods.

Consequently, increases in two-drug and three-drug oral/GLP-1-receptor antagonist-based combination regimens, and in combinations involving insulin, were seen after patients started empagliflozin treatment.

**Effectiveness and safety**

Clinical trials established that empagliflozin improves glycemic control with a low risk of hypoglycemia.\textsuperscript{15 23–26} The current study provides evidence of the effectiveness and safety of empagliflozin when used in routine clinical practice. Empagliflozin treatment was associated with significant reductions in mean HbA1c and mean fasting plasma glucose levels, and a significant increase in the proportion of patients achieving an HbA1c <6.5%, compared with the status prior to initiation. There was no increase in the rates of severe hypoglycemia. The risk of diabetic ketoacidosis could not be evaluated due to the low number of events. In fact, no such event occurred after start of empagliflozin within the study follow-up. There was also no increase in the rate of CKD after initiation of empagliflozin; in fact, a non-significant trend toward a reduced rate of CKD was seen after 6 months.

**Germany-specific aspects**

One aspect to be considered when evaluating the changing use of empagliflozin in Germany is its adoption in the German ‘disease management program (DMP) type-2 diabetes (T2D)’. At the end of April 2017, the Federal Joint Committee (G-BA), Germany’s highest decision-making body of the joint self-government of physicians, dentists, hospitals and health insurance funds, decided to add empagliflozin as a drug ‘with proven benefit on clinical outcomes’ recommended for patients with eCVD. This resolution became effective July 1, 2017.

G-BA’s decision to grant empagliflozin a considerable additional benefit in the AMNOG HTA procedure in September 2016 is a further aspect to be considered. Because of this we assume some beneficial effect on empagliflozin real-world use in Germany. However, the Germany-wide so-called practice specialty, exempting physicians’ empagliflozin prescriptions for patients with T2D/eCVD from budget restrictions, is considered to impact physicians’ prescribing behavior even more than the G-BA decision itself. This practice specialty became effective only in January/February 2017.

**Clinical implications**

The results of this study support the effectiveness and safety of empagliflozin in daily clinical practice. The findings are consistent with the known profile of empagliflozin from clinical trials, which necessarily involved a more restricted patient population.

Major guidelines recommend adding an SGLT-2 inhibitor or GLP-1 agonist with proven cardiovascular benefits to metformin in patients with T2DM and atherosclerotic cardiovascular disease (ASCVD), with empagliflozin and liraglutide, respectively, favored over other drugs from these classes because they have been shown to reduce both major adverse cardiovascular events and cardiovascular mortality.\textsuperscript{20 27 28} SGLT-2 inhibitors are recommended as add-on therapy for patients with ASCVD, heart failure or CKD.\textsuperscript{20} It should be noted that, although there is some evidence of a class effect on cardiovascular outcomes for SGLT-2 inhibitors, individual studies have produced varying results.\textsuperscript{20} Nonetheless, several observational studies support SGLT-2 inhibitors having a beneficial effect on cardiovascular outcomes in ‘real-world’ practice.\textsuperscript{29 30} It is likely that the use of this drug class will continue to increase in the future. The current study does not provide long-term outcome data for empagliflozin, but it does provide reassurance that the drug can be safely used in patients with T2DM, including those with cardiovascular comorbidity, who are managed in a routine practice setting.

**Limitations**

The main limitation of the study is that patients were recruited from specialized centers that were participating in diabetes registries, which could bias the results toward patients requiring specialist care. The cross-sectional nature of the study precludes the identification of causal links between findings. The strengths include the large number of patients that were enrolled and the routine practice setting, which means that the study provides evidence from ‘real-world’ clinical practice.

**CONCLUSIONS**

This study shows that in routine practice, empagliflozin is being prescribed to a broader range of patients and earlier in the treatment regimen over time. It is usually being added to an existing antidiabetic regimen and is increasingly being used in combination with metformin, GLP-1 A and/or insulin. In a ‘real-world’ setting, empagliflozin has a beneficial effect on glycemic control, with no increase in the rates of severe hypoglycemia.

**Author affiliations**

1. Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
2. Department of Gastroenterology and Endocrinology, University of Göttingen, Göttingen, Germany
3. Schwerpunktpraxis Diabetologie, Karlsruhe, Germany
4. Department of Gastroenterology and Endocrinology, University of Göttingen, Göttingen, Germany
5. Praxis für Innere Medizin, Kassel, Germany
6. Schwerpunktpraxis Diabetologie, Karlsruhe, Germany
7. Praxis für Innere Medizin, Rottweil, Germany
8. Gemeinschaftspraxis, Nienburg - Locum - Landsbergen, Germany
9. St Vincenz Krankenhaus, Limburg, Germany
10. Diabeteszentrum für Kinder und Jugendliche, Kinderkrankenhaus auf der Bult, Hannover, Germany
11. Boehringer Ingelheim Pharma GmbH und Co KG, Ingelheim, Germany
12. University Hospital, Freiburg, Germany
13. Boehringer Ingelheim Pharma GmbH und Co KG, Ingelheim, Germany
14. Diabeteszentrum für Kinder und Jugendliche, Kinderkrankenhaus auf der Bult, Hannover, Germany
15. G-BA, Germany’s decision to grant empagliflozin a considerably additional benefit in the AMNOG HTA procedure in September 2016 is a further aspect to be considered.

**Acknowledgements** We thank all participating centers of the DPV and DIVE initiatives.
Cardiovascular and Metabolic Risk

Contributors CW, KK, DR, RW-L, DE, JH and TD contributed to data collection. PB, SRT, MG, JF and LL defined the scope and the relevant parameters to be assessed in this work. PB and SRT designed the analysis, drafted the manuscript and created the figure. SRT was responsible for the statistical analyses. CW, KK, DR, RW-L, DE, JH, TD, MG, JF, LL, and JS contributed to the discussion and reviewed/edited the manuscript. SRT had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors approved the final manuscript to be submitted.

Funding The DPV registry was supported by the European Foundation for the Study of Diabetes (EFSO). Further financial support was provided by the German Diabetes Society (DDG) and the German Center for Diabetes Research (DDZ). The DPV registry received funding from Abbott, AstraZeneca, Bayer and Sanofi. These organizations were not involved in the analysis and interpretation of data, writing of the report or the decision to submit the article for publication. The present work was funded by Boehringer Ingelheim. MG, JF and LL, as employees of Boehringer Ingelheim, were involved in developing the concept, interpretation of data, writing of the report and the decision to submit for publication.

Competing interests JF and TD report grants and personal fees from Abbott, AstraZeneca, and Sanofi, outside the submitted work. PB reports to have received research support from the funders of DIVE. MG, JF and LL are employees of Boehringer Ingelheim. SRT, CW, KK, DR, RW-L, DE, and JH have no competing interests to disclose.

Patient consent for publication Not required.

Ethics approval The DPV initiative, which was established in 1995, was approved by the ethics committee of the University of Ulm, and data collection was approved by the local review boards. The DPV registry was established in Germany in 2011. The protocol was approved by the ethics committee of the Medical School of Hannover.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement The data sets generated and analyzed during the current study are not publicly available due to data privacy, but aggregated data may be available from the corresponding author on reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Peter Bramlage http://orcid.org/0000-0003-4970-2110

REFERENCES

1 Zimman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28.
2 Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323–34.
3 Madaan T, Akhtar M, Najmi AK. Sodium glucose cotransporter 2 (SGLT2) inhibitors: current status and future perspective. Eur J Pharm Sci 2016;93:244–52.
4 Schwab KO, Doerfer J, Hungele A, et al. Non-high-density lipoprotein cholesterol in children with diabetes: proposed treatment recommendations based on glycometric control, body mass index, age, sex, and generally accepted cut points. J Pediatr 2015;167:1436–9.
5 Bohn B, Schöltz C, Zimmer V, et al. Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis. Cardiovasc Diabetol 2016;15:72.
6 Danne T, Kaimhiel M, Koch A, et al. “Diabetes Versorgungs-Evaluation” (DIVE)—a national quality assurance initiative at physicians providing care for patients with diabetes]. Dtsch Med Wochenchr 2013:138:934–9 https://doi.org/
7 Bramlage P, Lanzinger S, van Mark G, et al. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases. Cardiovasc Diabetol 2019;18:33.
8 Schwanitz A, Denkinger M, Fasching P, et al. Comparison of MDRD, CKD-EPI, and Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes. J Diabetes Compl 2017;31:1376–83.
9 Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies observation report. Kidney Int 2011;80:17–28.
10 KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease: chapter 1: definition and classification of CKD. Kidney Int Suppl 2012;2013:19–62.
11 Neelaid J, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2016;13:119–26.
12 Hadjadj S, Rosenstock J, Meinicke T, et al. Initial combination of Empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care 2016;39:1718–26.
13 Hu J, Zou P, Zhang S, et al. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes. Expert Opin Pharmacother 2016;17:2471–7.
14 Scheen AJ. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opin Drug Saf 2016;17:387–48.
15 Ridderstrale M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocronol 2017;5:691–700.
16 Landgraf R, Aberle J, Birkenfeld AL, et al. [Treatment of Type-2 Diabetes]. Diabetologie 2019;14:S167–87.
17 DeFronzo RA, Lewin A, Patil S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38:384–93.
18 Søfteland E, Meier JJ, Vangen B, Eirik S, Meier Juris J, Bente V, et al. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. Diabetes Care 2017;40:201–9.
19 Rosenstock J, Hansen L, Zee P, Julio R, Lars H, Pamela Z, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized, double-blind trial of saxagliptin plus dapagliflozin compared with the single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015;38:376–83.
20 Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes. 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 2018;41:2669–701.
21 Rosenstock J, Jelsaka A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17:936–48.
22 Rosenstock J, Jelsaka A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014;37:21–23.
23 Zhang Y-J, Han S-L, Sun X-F, et al. Efficacy and safety of empagliflozin for type 2 diabetes mellitus: meta-analysis of randomized controlled trials. Medicine 2018;97:e12843.
24 Frampton JE. Empagliflozin: a review in type 2 diabetes. Drugs 2018;78:1037–48.
25 Levine MJ. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev 2017;13:405–23.
26 Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of Empagliflozin in patients with type 2 diabetes. Clin Ther 2016;38:1299–313.
27 American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018;41:S73–85.
28 American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:S90–102.
29 Zou C-Y, Liu X-K, Sang Y-Q, et al. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis. Medicine 2019;88:e18245.
30 Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular morbidity and mortality in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocronol 2017;5:709–17.
31 Pasternak B, Ueda P, Elissass B, et al. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ 2019;366:j4772.